Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Mite Allergy

NCT02661854 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

186

Enrollment

INDUSTRY

Sponsor class

Conditions

Rhinitis
Rhinoconjunctivitis

Interventions

BIOLOGICAL: MM09 Mannosylated 5.000 subcutaneous
BIOLOGICAL: MM09 Mannosylated 10.000 subcutaneous
BIOLOGICAL: MM09 Mannosylated 30.000 subcutaneous
BIOLOGICAL: MM09 Mannosylated 50.000 subcutaneous
BIOLOGICAL: MM09 Mannosylated 5.000 sublingual
BIOLOGICAL: MM09 Mannosylated 10.000 sublingual
BIOLOGICAL: MM09 Mannosylated 30.000 sublingual
BIOLOGICAL: MM09 Mannosylated 50.000 sublingual
BIOLOGICAL: Subcutaneous placebo
BIOLOGICAL: Sublingual placebo

Sponsor

Inmunotek S.L.